Skip to main content
PMC home page
Springer logoLink to Springer
. 2018 Apr 14;34(3):388–400. doi: 10.1007/s12640-018-9898-y

The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells

Kamila Siedlecka-Kroplewska 1,✉, Agata Wrońska 1, Grzegorz Stasiłojć 2, Zbigniew Kmieć 1
PMCID: PMC6154176  PMID: 29656349

Abstract

Synthetic cathinones are psychoactive substances, derivatives of a natural psychostimulant cathinone. Although many synthetic cathinones have lost their legal status in many countries, their abuse still continues worldwide. Recently, they have been reported to exert neurotoxic effects in vitro and in vivo. The molecular mechanisms of their action have not been fully elucidated. Recently, they have been linked to the induction of oxidative stress, autophagy, and apoptosis. The aim of this study was to investigate whether 3-fluoromethcathinone (3-FMC), a synthetic cathinone, is able to induce oxidative stress, autophagy, and apoptosis in HT22 immortalized mouse hippocampal cells. We found that treatment of HT22 cells with this compound results in a concentration-dependent increase in the intracellular production of reactive oxygen species. Moreover, 3-FMC induced concentration-dependent conversion of cytosolic LC3-I to membrane-bound LC3-II and formation of autophagic vacuoles. Additionally, the level of p62/SQSTM1 protein decreased after 3-FMC treatment, suggesting that accumulation of autophagic vacuoles resulted from activation rather than inhibition of autophagy. Our results also showed that 3-FMC at millimolar concentration is able to induce caspase-dependent apoptotic cell death in HT22 cells. Our findings suggest that abuse of 3-FMC may disturb neuronal homeostasis and impair functioning of the central nervous system.

Keywords: Designer drugs, Synthetic cathinones, 3-Fluoromethcathinone, Oxidative stress, Autophagy, Apoptosis

Introduction

Synthetic cathinones are psychoactive substances, derivatives of a naturally occurring alkaloid cathinone (Balint et al. 2009; Zawilska and Wojcieszak 2013). Recently, they have gained popularity as recreational drugs or “legal highs” (ACMD 2010a; EMCDDA 2017). The new psychoactive substances, also known as “designer drugs,” have emerged as legal alternatives to classic illegal drugs of abuse such as cocaine or 3,4-methylenedioxy-N-methyl-amphetamine (MDMA). Although many cathinones, e.g., 4-methylmethcathinone (mephedrone), 3,4-methylenedioxypyrovalerone (MDPV), 3,4-methylenedioxy-N-methylcathinone (methylone), 3-fluoromethcathinone (3-FMC), and 4-fluoromethcathinone (4-FMC), have lost their legal status in many countries, their abuse still continues worldwide (EMCDDA 2017; Assi et al. 2017).

The molecular mechanism of action of synthetic cathinones is based on their interaction with transporters of monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine (Cozzi et al. 1999; Simmler et al. 2013, 2014; Baumann et al. 2013). Many synthetic cathinones such as mephedrone, methylone, and MDPV were shown to exhibit high blood-brain barrier permeability in an in vitro model (Simmler et al. 2013; Martínez-Clemente et al. 2013). Users compared effects of these substances with those elicited by MDMA and cocaine (Assi et al. 2017; Carhart-Harris et al. 2011). The “positive/desired” effects reported by users were euphoria, stimulation, and empathy (Winstock et al. 2011b; Assi et al. 2017; Carhart-Harris et al. 2011; Zawilska and Wojcieszak 2013; ACMD 2010b). However, it should be emphasized that adverse effects were also reported, regarding mostly the cardiovascular, nervous, and gastrointestinal systems. For instance, in the cardiovascular system, hypertension, tachycardia, chest pain, palpitations, cardiac arrest, and myocarditis were reported after the use of cathinones (Assi et al. 2017; Zawilska and Wojcieszak 2013; Winstock et al. 2011a; Prosser and Nelson 2012; ACMD 2010b). The toxic effects concerning the nervous system included hyperthermia, insomnia, headache, dizziness, memory problems, confusion, blurred vision, bruxism, paresthesias, mydriasis, tremors, seizures, hallucinations/delusions, anxiety, agitation, and psychosis (Vallersnes et al. 2016; Winstock et al. 2011a, b; Zawilska and Wojcieszak 2013; Prosser and Nelson 2012; ACMD 2010b). Symptoms regarding the gastrointestinal system were abdominal pain, nausea, vomiting, and anorexia (Zawilska and Wojcieszak 2013; Winstock et al. 2011a; Prosser and Nelson 2012; ACMD 2010b).

Many drugs of abuse have been demonstrated to impair cognitive skills and exert neurotoxic effects (den Hollander et al. 2012; Gardner et al. 2009; Parrott 2000; Reneman et al. 2001; Thompson et al. 2004). MDMA, an active component of “ecstasy,” was shown to be toxic to brain serotonin neurons (Reneman et al. 2001). There is evidence of hippocampal atrophy in chronic users of “ecstasy” (den Hollander et al. 2012; Gardner et al. 2009). Memory impairments in “ecstasy” users were also documented (Parrott 2000). Additionally, chronic methamphetamine abuse was shown to reduce hippocampal volume and hippocampal deficits correlated with impaired memory performance in its users (Thompson et al. 2004). Accumulating data suggest that synthetic cathinones may also be neurotoxic and impair functions of the nervous system (Hadlock et al. 2011; Marusich et al. 2012; López-Arnau et al. 2014, 2015; Martínez-Clemente et al. 2014; den Hollander et al. 2013). In mice, methylone induced astrogliosis in the hippocampus as well as dopaminergic and serotonergic impairment (López-Arnau et al. 2014). Its administration in rats caused the depletion of serotonin and its transporters’ levels (den Hollander et al. 2013). Noteworthy, mephedrone was reported to impair working memory in humans (Freeman et al. 2012). Interestingly, there are different results regarding its neurotoxicity in animal models (Hadlock et al. 2011; López-Arnau et al. 2015; Martínez-Clemente et al. 2014; Baumann et al. 2012; den Hollander et al. 2013, Angoa-Pérez et al. 2012, 2014). Some studies on long-term neurochemical effects of mephedrone in rodents suggest lack of neurotoxicity (Baumann et al. 2012; den Hollander et al. 2013; Angoa-Pérez et al. 2012, 2014), whereas other studies indicate that it exerts neurotoxic effects (Hadlock et al. 2011; Martínez-Clemente et al. 2014; López-Arnau et al. 2015). Probably, the discrepancies are due to different experimental design, e.g., species, dosage, and ambient temperature as well as relation of experimental conditions to drug pharmacokinetics and pharmacodynamics.

Recent in vitro studies have also shown that synthetic cathinones may exhibit neurotoxic properties. However, the precise molecular mechanisms of their action have not been fully elucidated. Noteworthy, mephedrone elicited cytotoxicity against cortical neurons isolated from mouse embryos (Martínez-Clemente et al. 2014). Pyrovalerone and its derivatives reduced the viability of human neuroblastoma SH-SY5Y cells (Wojcieszak et al. 2016). Our recent investigation revealed that 3-FMC inhibits growth and induces cell cycle arrest in HT22 immortalized mouse hippocampal cells (Siedlecka-Kroplewska et al. 2014). Recently, some synthetic cathinones have been demonstrated to induce oxidative stress, autophagy, and apoptosis in neuronal cells (Valente et al. 2017; Matsunaga et al. 2017). Methylone and MDPV induced oxidative stress, autophagy, and apoptosis in differentiated human neuroblastoma SH-SY5Y cells (Valente et al. 2017). Similarly, treatment of human neuroblastoma SK-N-SH cells with α-pyrrolidinononanophenone (α-PNP) led to oxidative stress, autophagy, and apoptotic cell death (Matsunaga et al. 2017). Taking into account these findings, the aim of this study was to examine whether 3-FMC induces oxidative stress, autophagy, and apoptosis in HT22 hippocampal cells. Our results provide evidence that the mechanism of action of this synthetic cathinone in HT22 cells involves induction of oxidative stress as well as activation of autophagy. We also found that 3-FMC at millimolar concentrations is able to induce caspase-dependent apoptotic cell death.

Materials and Methods

Chemicals

3-Fluoromethcathinone was purchased from LGC Standards (UK). Stock solutions of this compound were prepared in sterile physiological saline solution and diluted to indicated concentrations shortly before use. Rabbit anti-LC3 primary antibodies were purchased from Medical & Biological Laboratories Co. (Japan). Mouse anti-p62 antibody was obtained from Santa Cruz Biotechnology, Inc. (USA). Cy3-conjugated goat anti-rabbit secondary antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. (USA). Horseradish peroxidase-conjugated mouse anti-GAPDH primary antibodies, horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies, and horseradish peroxidase-conjugated rabbit anti-mouse secondary antibodies were purchased from Sigma-Aldrich (USA). H2DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) was obtained from Molecular Probes (USA). Hoechst 33342 was purchased from Sigma-Aldrich (USA). All other reagents, obtained from commercial suppliers, were of analytical grade.

Cell Culture

The immortalized mouse hippocampal HT22 cell line was kindly provided by Professor M. Woźniak (Department of Medical Chemistry, Medical University of Gdańsk, Poland). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2, in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, USA), supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, USA), 100 IU/ml penicillin (Sigma-Aldrich, USA), and 100 μg/ml streptomycin (Sigma-Aldrich, USA).

Measurement of Intracellular Reactive Oxygen Species

HT22 cells were seeded in 6-well plates (2 × 105cells per well) and allowed to attach for 24 h. Next, cells were incubated with 3-FMC for 45 or 90 min. Simultaneously, control cells were incubated in the absence of 3-FMC. Thirty minutes before the end of incubation with 3-FMC, H2DCFDA (final concentration 10 μM) was added. Cells were then washed, suspended in ice-cold phosphate-buffered saline (PBS), and analyzed for DCF fluorescence by flow cytometry (Becton Dickinson FACSCalibur, USA).

Western Blotting Analysis

HT22 cells were incubated in the absence (control) or presence of 3-FMC for 24 h. After incubation, cell lysates were prepared using Mammalian Cell Extraction Kit (BioVision, Inc., USA). The total concentration of proteins in cell lysates was determined using the Bradford protein assay. Protein samples (45 μg of total protein per sample) were separated electrophoretically by SDS-PAGE (12%) and transferred onto PVDF membrane. The membrane was incubated with 5% non-fat dry milk in TBS (tris-buffered saline) at room temperature (RT) for 1 h. After washing with TBST (0.1% Tween20 in TBS), the membrane was incubated with specific rabbit anti-LC3 primary antibodies (1:4000) or mouse anti-p62 primary antibodies (1:200) at 4 °C overnight, and after subsequent washing incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (1:10,000) for 2 h at RT. The membrane was also incubated with horseradish peroxidase-conjugated anti-GAPDH primary antibodies (1:50,000, 1 h at RT) for loading control. The bound antibodies were detected by the enhanced chemiluminescence method using the Chemiluminescent Peroxidase Substrate (Sigma-Aldrich, USA). The densitometric analysis of immunoreactive protein bands was performed using Quantity One Software (Bio-Rad, USA).

Immunofluorescent Analysis

HT22 cells were seeded in 4-well tissue culture chamber (8 × 104 cells per well) on PCA slide (Sarstedt, Germany) and allowed to attach for 24 h. Next, cells were incubated in the absence (control) or presence of 3-FMC for 24 h. Following incubation, cells were washed with PBS, fixed, and permeabilized for 5 min in cold methanol at − 20 °C. After washing with PBS, cells were incubated for 30 min (RT) with 10% FBS (fetal bovine serum, 10% FBS in PBS). Next, cells were washed with PBS and incubated with specific rabbit anti-LC3 primary antibodies (1:500) for 1 h (RT). After washing with PBS, cells were incubated with Cy3-conjugated anti-rabbit secondary antibodies (1:600) for 1 h (RT) in the dark. Following washing with PBS, cells were stained with 5 μg/ml Hoechst 33342 for 15 min (RT) in the dark. Next, samples were mounted in the Permafluor mounting medium (Thermo Scientific, USA) and covered with glass coverslips. Slides were examined by the confocal microscope system FV10i (Olympus, Japan). The images were obtained using × 60 objective lens.

Hoechst 33342 Staining

Adherent cells undergoing cell death tend to detach from the surface of tissue culture flasks. In order to prevent cell loss and better examine nuclear morphology of 3-FMC-treated cells, we tried to improve our standard procedure of cell staining for confocal microscopy. HT22 cells were seeded in 6-well plates (2 × 105 cells per well) and allowed to attach for 24 h. Next, cells were incubated in the absence (control) or presence of 3-FMC for 24 h. After incubation, all cells were collected, i.e., including cells detached from the surface of the culture flask as well as cells collected after trypsinization. Following washing with PBS, cells were cytocentrifuged (1 × 105 cells per slide) onto microscopic poly-L-lysine-coated slides (Sigma-Aldrich, USA). After fixation and permeabilization in cold methanol for 5 min at − 20 °C, cells were washed with PBS and stained with 5 μg/ml Hoechst 33342 for 15 min (RT) in the dark. Next, samples were mounted in the Permafluor mounting medium (Thermo Scientific, USA) and covered with glass coverslips. Slides were examined by the confocal microscope system FV10i (Olympus, Japan). The images were obtained using × 60 objective lens.

Annexin V-FITC/PI Assay

Phosphatidylserine externalization was examined using Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, USA). HT22 cells were seeded in 6-well plates (2 × 105cells per well) and allowed to attach for 24 h. Next, cells were incubated in the absence (control) or presence of 3-FMC for 24 h. Following incubation, cells were stained with FITC-conjugated annexin V and PI according to the manufacturer’s protocol. Samples were analyzed by flow cytometry (Becton Dickinson FACSCalibur, USA).

Caspase-3 Activity Assay

Caspase-3 activity was measured using FITC-conjugated Monoclonal Active Caspase-3 Antibody Apoptosis Kit I (BD Pharmingen, USA). HT22 cells were seeded in 6-well plates (2 × 105 cells per well) and allowed to attach for 24 h. Next, cells were incubated in the absence (control) or presence of 3-FMC for 24 h. Following incubation, cells were stained with FITC-conjugated anti-active caspase-3 antibody according to the manufacturer’s protocol and flow cytometric analyses were performed (Becton Dickinson FACSCalibur, USA).

Statistical Analysis

Statistical analysis was performed using Statistica 12 software (StatSoft, Poland). Data are expressed as means ± SD. Statistical differences between samples were evaluated using the non-parametric Mann-Whitney U test. Differences were considered significant at *p < 0.05 and **p < 0.01.

Results

Effect of 3-FMC on Generation of Reactive Oxygen Species

We have previously found that 3-FMC is cytotoxic to HT22 cells at relatively high, millimolar concentration since 24 h of treatment with 1, 2, or 4 mM 3-FMC reduced the viability of HT22 cells by 16, 34, and 76%, respectively (Siedlecka-Kroplewska et al. 2014). To find out whether the mechanism of action of 3-FMC involves oxidative stress, we examined the effect of this compound on the intracellular production of reactive oxygen species (ROS). Our results showed that the formation of ROS increased after treatment of HT22 cells with 3-FMC. Compared to control cells, exposure to 2 or 4 mM 3-FMC resulted in a statistically significant increase in ROS formation after 45 min (Fig. 1a), whereas 1 mM 3-FMC significantly induced ROS generation after 90 min of incubation (Fig. 1b).

Fig. 1.

Fig. 1

Open in a new tab

Effect of 3-FMC on intracellular ROS production in HT22 cells. HT22 cells were treated with 3-FMC for 45 min (a) or 90 min (b). Cells were analyzed by flow cytometry as described in Materials and Methods. Data are presented as means ± SD of three independent experiments, n = 4 (n, number of samples per each experimental point), *p < 0.05, statistically significant differences compared to control (untreated cells)

Detection of Autophagy in 3-FMC-Treated HT22 Cells

The microtubule-associated protein 1 light chain 3 (LC3) plays an important role in autophagy (Eskelinen 2005). During autophagy, the cytosolic form of LC3 (LC3-I) is conjugated with phosphatidylethanolamine forming the membrane-bound form of LC3 (LC3-II). Detection of LC3-II is a hallmark of the formation of autophagic vacuoles. To investigate the effects of 3-FMC on autophagic pathways, we examined the conversion of LC3-I to LC3-II. The western blotting analysis revealed that after 24 h of treatment of HT22 cells with 3-FMC, the level of LC3-II increased, indicating processing of LC3-I and formation of LC3-II. This effect was concentration-dependent and was most pronounced at the 3-FMC concentration of 4 mM (Fig. 2). The relative LC3-II level (normalized to loading control GAPDH) after exposure to 1, 2, and 4 mM 3-FMC was 1.3, 2.0, and 4.4, respectively. The relative LC3-I level after 3-FMC treatment decreased compared to control and for 1, 2, and 4 mM 3-FMC, it was equal to 0.6, 0.2, and 0.2, respectively (Fig. 2).

Fig. 2.

Fig. 2

Open in a new tab

Detection of autophagy. HT22 cells were treated with 1, 2, or 4 mM 3-FMC for 24 h. The relative protein levels of LC3-I, LC3-II, and p62 normalized to loading control GAPDH were quantitated by densitometry as described in Materials and Methods. Similar results were obtained in three independent experiments. C—control, untreated cells

The immunofluorescent staining with anti-LC3 antibodies revealed the accumulation of LC3-positive dots in HT22 cells treated with 1, 2, or 4 mM 3-FMC for 24 h (Fig. 3), suggesting accumulation of autophagic vacuoles. It was particularly evident after exposure to 4 mM 3-FMC. In control cells, LC3 staining was mostly diffuse, indicative of cytosolic localization of LC3 protein (Fig. 3).

Fig. 3.

Fig. 3

Open in a new tab

Immunofluorescent analysis. Confocal micrographs of HT22 cells treated with 1, 2, and 4 mM 3-FMC for 24 h. Cells were incubated with primary anti-LC3 antibodies. Following incubation with Cy3-conjugated secondary antibodies and Hoechst 33342, cells were examined by confocal microscopy as described in Materials and Methods. Data are representative of three independent experiments. Bars 10 μm, control—untreated cells, arrowheads—autophagic vacuoles, short arrows—nucleoli, long arrow—a cell undergoing mitosis, asterisks—newly formed cells after cell division

In order to find out whether the accumulation of autophagic vacuoles in HT22 cells results from activation or inhibition of autophagy, we evaluated the level of p62/SQSTM1 protein. The p62 protein, also known as sequestosome-1 (SQSTM1), interacts with ubiquitinated proteins targeting them for degradation by autophagy (Klionsky et al. 2012). Our results showed that its level in HT22 cells decreased after 3-FMC treatment (Fig. 2). The relative p62/SQSTM1 level (normalized to loading control GAPDH) after exposure to 1, 2, and 4 mM 3-FMC was 0.8, 0.2, and 0.1, respectively (Fig. 2).

Detection of Cell Death

Our previous results revealed that treatment of HT22 cells with 3-FMC led to an increase in the number of cells in the sub-G1 fraction, indicative of apoptosis (Siedlecka-Kroplewska et al. 2014). In line with this finding, in the present study, we examined markers of apoptotic cell death such as phosphatidylserine externalization, caspase-3 activation, chromatin condensation, and fragmentation of cell nuclei.

Loss of the plasma membrane asymmetry manifested by phosphatidylserine externalization belongs to early apoptotic events (Galluzzi et al. 2012). As shown in Fig. 4a, the effect of 3-FMC on phosphatidylserine externalization was concentration-dependent. The prominent changes were observed after treatment with 4 mM 3-FMC, when annexin V+/PI− cells (corresponding to early apoptotic cells) and annexin V+/PI+ cells (corresponding to late apoptotic/necrotic cells) constituted about 11 and 27% of the total measured cell population, respectively (Fig. 4a). Exposure of HT22 cells for 24 h to 1 and 2 mM 3-FMC had a negligible effect on fractions of annexin V+/PI− cells and annexin V+/PI+ cells.

Fig. 4.

Fig. 4

Open in a new tab

Detection of cell death. a Phosphatidylserine externalization induced by 3-FMC in HT22 cells (annexin V-FITC/PI staining, flow cytometry analysis). Cells were treated with 1, 2, or 4 mM 3-FMC for 24 h. Data are presented as means ± SD of three independent experiments. n = 4–5,*p < 0.05, statistically significant differences compared to control (untreated cells). b Caspase-3 activation in 3-FMC-treated HT22 cells (flow cytometry analysis). Cells were treated with 1, 2, or 4 mM 3-FMC for 24 h. Data are presented as means ± SD of three independent experiments. n = 4–7, **p < 0.01, statistically significant differences compared to control (untreated cells). c Confocal micrographs of HT22 cells treated with 4 mM 3-FMC for 24 h. Cells were stained with Hoechst 33342 as described in Materials and Methods. Data are representative of three independent experiments. Bars 10 μm, control—untreated cells, short arrows—nucleoli, arrowheads—fragments of cell nuclei, asterisks—cell nuclei with condensed chromatin

We found that 3-FMC-induced cell death was associated with caspase-3 activation (Fig. 4b). The active caspase-3 participates in the executive stage of apoptosis (Galluzzi et al. 2012). After 24 h of incubation of HT22 cells with 1 or 2 mM 3-FMC, 5% and over 8% of the total measured cell population, respectively, showed caspase-3 activity (Fig. 4b). This effect was most prominent after 24 h of treatment with 4 mM 3-FMC, since the fraction of cells with active caspase-3 was then over 30% (Fig. 4b).

Changes of the nuclear morphology typical for apoptotic cell death include chromatin condensation and nuclear fragmentation (Prokhorova et al. 2015). The immunofluorescent analysis revealed that after exposure to 1 or 2 mM 3-FMC, the majority of HT22 cells exhibited intact cell nuclei with well visible nucleoli (Fig. 3). Noteworthy, at the same time, LC3-positive structures were present, indicative of autophagic vacuoles. Both accumulation of autophagic vacuoles and an intact nucleus are characteristics of cells undergoing autophagy (Liu and Ouyang 2014). Interestingly, after treatment with 1 mM 3-FMC, even cells undergoing mitosis were observed (Fig. 3). After 24-h exposure of HT22 cells to 4 mM 3-FMC, the majority of cells exhibited intact nuclear architecture, accompanied by the presence of autophagic vacuoles (Fig. 3). However, confocal micrographs revealed that the shape of cells treated with 4 mM 3-FMC changed and was more rounded in comparison to untreated cells and cells treated with lower concentrations of this drug, suggesting decreased cell adhesion to the surface of the culture flask. Annexin V/PI double staining analysis revealed a high number of dead cells after treatment with 4 mM 3-FMC (Fig. 4a). Considering that adherent cells undergoing death tend to detach from the surface of the culture flask and may be lost during washing steps, we modified our standard procedure of slides preparation for confocal microscopy as described in Materials and Methods. Noteworthy, the detached cells may be suspected of pronounced apoptotic nuclear alterations. Using our improved method, we detected the presence of nuclear fragmentation and chromatin condensation after 24 h of treatment with 4 mM 3-FMC (Fig. 4c).

Discussion

Recently, several in vitro and in vivo studies have shown that synthetic cathinones may exert neurotoxic effects (López-Arnau et al. 2014; Siedlecka-Kroplewska et al. 2014, Matsunaga et al. 2017; Valente et al. 2017; Hadlock et al. 2011; Martínez-Clemente et al. 2014; López-Arnau et al. 2015; den Hollander et al. 2013; Marusich et al. 2012). There is evidence indicating that these drugs, especially at high concentrations, may cause neuronal cell death (López-Arnau et al. 2014; Siedlecka-Kroplewska et al. 2014; Matsunaga et al. 2017; Valente et al. 2017). The precise molecular mechanisms of their action have not been fully elucidated. In this study, we used HT22 immortalized mouse hippocampal cells as an in vitro model of neuronal cells. HT22 cell line is widely used to study glutamate toxicity as well as Alzheimer’s and Parkinson’s diseases (Kumari et al. 2012; Fukui et al. 2009; Yang et al. 2015; Jensen et al. 2017; Gliyazova and Ibeanu 2016; Kang et al. 2013). Noteworthy, the hippocampus is the unique region of the brain, where the neural stem cells can be found (Kempermann et al. 2015). It plays a crucial role in the formation of memory (Yonelinas 2013). Accumulating evidence suggests that drug abuse may lead to hippocampal atrophy and memory deficits (den Hollander et al. 2012; Gardner et al. 2009; Parrott 2000; Thompson et al. 2004).

In the present study, we demonstrate that 3-FMC induces oxidative stress in HT22 cells. After treatment with 3-FMC, we observed a concentration-dependent increase in the intracellular production of ROS. In agreement with our finding, recent in vitro studies have indicated that oxidative stress may also be involved in the mechanism of action of other synthetic cathinones such as α-PNP, methylone, and MDPV (Matsunaga et al. 2017; Valente et al. 2017). Exposure to α-PNP led to oxidative stress in human neuronal SK-N-SH cells (Matsunaga et al. 2017). Methylone and MDPV increased the production of reactive oxygen and nitrogen species in human dopaminergic SH-SY5Y cells (Valente et al. 2017). Interestingly, other psychostimulant drugs such as amphetamine or methamphetamine were also shown to induce oxidative stress in neuronal cells (Huang et al. 1997; Cadet and Brannock 1998; Brown and Yamamoto 2003; Tian et al. 2009; Huang et al. 2017). The designer drug N-benzylpiperazine (BZP) induced oxidative stress in human glioblastoma LN-18 cells (Persona et al. 2016). It is important to note that the overproduction of reactive oxygen or nitrogen species triggers oxidative damage of cellular structures and disturbs cellular homeostasis (Halliwell 1996).

We found that 3-FMC activates autophagy in HT22 cells. Noteworthy, the higher the 3-FMC concentration, the more pronounced were the markers of autophagy. Confocal microscopy revealed an increased number of LC3-positive structures in 3-FMC-treated HT22 cells. Moreover, we detected conversion of cytosolic LC3-I to membrane-bound LC3-II, indicative of the formation of autophagic vacuoles. The western blotting analysis revealed a concentration-dependent increase in LC3-II expression. The cytosolic LC3-I protein serves as a substrate to form the LC3-II protein, present in membranes of autophagosomes, nascent amphisomes, and nascent autolysosomes (Eskelinen 2005). Both accumulation of autophagic vacuoles and an elevated LC3-II level may suggest upregulation of autophagy; however, they may also indicate inhibition of autophagic flux associated with impaired degradation and reduced turnover of autophagosomes (Klionsky et al. 2012). Therefore, in order to better evaluate the autophagic status, we examined the level of p62/SQSTM1 protein. An increased level of p62/SQSTM1 was shown to correlate with the inhibition of autophagy, whereas its decreased level with activation of autophagy (Klionsky et al. 2012). We found that p62/SQSTM1 protein level decreased after 3-FMC treatment, suggesting that accumulation of autophagic vacuoles in HT22 cells resulted from activation rather than inhibition of autophagy.

Autophagy is an evolutionarily conserved process during which damaged or misfolded proteins as well as damaged cell organelles can be eliminated (Yang and Klionsky 2010). It is active at basal level in virtually all cells and serves mainly as a prosurvival mechanism underlying cellular homeostasis. In neuronal cells, it is essential to maintain their functions. Insufficient or impaired autophagic activity has been described in neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and HIV-associated neurocognitive disorders (Cai et al. 2016). However, autophagy may also function as a cell death mode known as autophagic cell death (Galluzzi et al. 2012). There is a limited number of studies demonstrating that cell death is executed by autophagy (Galluzzi et al. 2012). In most cases, autophagy appears to be a cytoprotective response activated by dying cells (Galluzzi et al. 2012; Kroemer and Levine 2008). Autophagy can be upregulated in response to nutrient depletion, hypoxia, or oxidative stress (Yang and Klionsky 2010). Many chemical compounds induce cellular stress and activate autophagy as an adaptive stress-response and a prosurvival mechanism (Yang et al. 2011; Eskelinen 2011). The cytoprotective role of autophagy may be related then to clearance of oxidized or aggregated proteins and damaged cell organelles. Accumulating evidence suggests that autophagy may be implicated in the mechanism of action of drugs of abuse. Numerous psychoactive substances including MDMA, methamphetamine, cocaine, α-PNP, methylone, and MDPV were found to induce autophagy (Li et al. 2014, 2016; Mercer et al. 2017; Kanthasamy et al. 2006; Chandramani Shivalingappa et al. 2012; Larsen et al. 2002; Cao et al. 2016; Matsunaga et al. 2017; Valente et al. 2017). Interestingly, methylone and MDPV were shown to induce both oxidative stress and autophagy in SH-SY5Y cells (Valente et al. 2017). α-PNP also led to oxidative stress induction as well as autophagy upregulation in SK-N-SH cells (Matsunaga et al. 2017). In the present study, oxidative stress induced by 3-FMC in HT22 cells may result in damage of proteins or organelles. Thus, upregulation of autophagy in 3-FMC-treated HT22 cells may appear as a consequence of disturbed cellular homeostasis. The decreased level of p62/SQSTM1 protein in 3-FMC-treated HT22 cells suggests autophagy activation with concomitant degradation of damaged proteins or damaged cellular organelles. Of note, p62 protein serves as a selective autophagy receptor involved in autophagic clearance of misfolded proteins, protein aggregates, or depolarized mitochondria, whose efficient elimination is critical for cellular homeostasis and survival (Rogov et al. 2014). p62 interacts with ubiquitinated autophagy substrates and LC3, becomes incorporated into autophagosomes, and subsequently degraded (Klionsky et al. 2012). Therefore, it can be speculated that autophagy activated in our experimental model appears as a prosurvival process. However, this hypothesis requires further investigation. Valente et al. demonstrated that antioxidants were able to attenuate generation of reactive oxygen and nitrogen species as well as partially inhibit autophagy and apoptosis induced by methylone and MDPV in SH-SY5Y cells, supporting the role of autophagy as a cellular self-defense response against oxidative stress (Valente et al. 2017).

Our results revealed that 3-FMC is able to induce apoptotic cell death in HT22 cells. This effect was prominent after treatment of cells with 4 mM 3-FMC; whereas at a lower concentration of this drug, it was negligible. The cell death mechanism was associated with caspase-3 activation and phosphatidylserine externalization. Morphological changes characteristic for apoptotic cell death such as chromatin condensation and fragmentation of cell nuclei were also observed. These findings corroborate results of our previous study (Siedlecka-Kroplewska et al. 2014). Four millimolar 3-FMC significantly increased the number of HT22 cells in the sub-G1 fraction (Siedlecka-Kroplewska et al. 2014), corresponding to the low molecular weight DNA fragments, indicative of apoptotic internucleosomal DNA fragmentation (Wlodkowic et al. 2011).

Taking into account the above findings, after treatment with 1 or 2 mM 3-FMC, only autophagy markers were observed in HT22 cells; whereas after exposure to 4 mM 3-FMC, both autophagic and apoptotic characteristics were detected. Thus, 3-FMC induced autophagy or both autophagy and apoptosis, depending on its concentration. In agreement with our results, recent in vitro studies also showed induction of both autophagy and apoptosis after treatment with other synthetic cathinones (Valente et al. 2017; Matsunaga et al. 2017). After treatment of HT22 cells with 1 or 2 mM 3-FMC, the number of dead cells was negligible, which supports the hypothesis that autophagy activation may be a cytoprotective cell response. However, toxicity of 4 mM 3-FMC was probably too high to be prevented by autophagy. Therefore, the number of dead cells dramatically increased. Induction of apoptosis by 4 mM 3-FMC in HT22 cells indicates that apoptotic pathways are involved in the mechanism of cell death. Numerous studies suggest that there is an interplay between autophagy and apoptosis (Thorburn 2008). Autophagic and apoptotic signaling pathways share some mediators, e.g., Beclin-1 interacts with anti-apoptotic Bcl-2 family proteins (Thorburn 2008). Autophagy as a prosurvival mechanism may block or delay apoptotic cell death. Intriguingly, caspase activation may serve as a molecular switch between autophagy and apoptosis (Wu et al. 2014). Activated caspases degrade autophagic proteins and inhibit autophagic response determining cell fate. In the present study, the number of HT22 cells with active caspase-3 significantly increased after treatment with 4 mM 3-FMC, suggesting a possible switch from autophagy to apoptosis. However, further studies are needed to confirm this hypothesis.

Our finding that relatively high, millimolar concentrations of 3-FMC exerted significant biological effects in neuronal HT22 cells is consistent with reports of other authors concerning in vitro studies on drugs of abuse. For example, methylone and MDPV reduced viability of SH-SY5Y cells by 60% at the concentration of 2.797 and 1.693 mM, respectively (Valente et al. 2017). Moreover, methylone affected viability of cultured cortical neurons and the calculated LD50 value after 24 and 48 h of incubation was over 1 mM (López-Arnau et al. 2014). Other drugs including MDMA or methamphetamine also exerted cytotoxic effects in vitro at millimolar concentrations (Li et al. 2014, 2016; Mercer et al. 2017; Huang et al. 2017). It is difficult to predict what would be the 3-FMC concentration in the human brain in vivo after its administration. It may depend on the administration route as well as the ability of this drug to penetrate the blood-brain barrier. The most common administration routes of synthetic cathinones reported by users are insufflation and oral ingestion (Freeman et al. 2012; Assi et al. 2017). The less common routes are intravenous, subcutaneous, intramuscular injections as well as rectal insertion, smoking, and insertion in the eye (eyeballing) (Assi et al. 2017). Assuming the average peripheral blood volume of 5 L and intravenous administration route, the calculated 3-FMC dose leading to its 1, 2, or 4 mM blood concentration is equal to 1.09, 2.18, and 4.35 g, respectively. Noteworthy, based on users’ self-reports, doses depend on the drug and the administration route and range from a few milligrams to over 1–2 g in a single session (Busardò et al. 2015). However, higher doses were also documented (Busardò et al. 2015; EMCDDA 2010). According to case reports concerning synthetic cathinone-related intoxications, users reported doses up to 7 g (EMCDDA 2010). Some users reported to use drugs over several consecutive days (Winstock et al. 2011b). The risk of overdosing seems to be high, since users experience a desire to redose (Winstock et al. 2011b; Freeman et al. 2012). It should be emphasized that there are numerous reports on acute and lethal intoxication with synthetic cathinones (Boulanger-Gobeil et al. 2012; Winder et al. 2013; Corkery et al. 2012; Adamowicz et al. 2013; Marinetti and Antonides 2013; Cosbey et al. 2013; Antonowicz et al. 2011; Lusthof et al. 2011; Wood et al. 2011; Murray et al. 2012; Brandt et al. 2010; Schifano et al. 2012; Maskell et al. 2011; Warrick et al. 2012; Wikström et al. 2010; Imam et al. 2013).

In conclusion, our results provide evidence that 3-FMC induces oxidative stress and activates autophagy in HT22 neuronal cells. We propose that autophagy triggered by oxidative damage in 3-FMC-treated HT22 cells may appear as a cellular defense mechanism, however, when it cannot prevent toxicity of a high dose of 3-FMC apoptotic pathways become activated. Further studies may help understand molecular mechanisms of 3-FMC neurotoxicity. Noteworthy, the implication of oxidative stress in the mechanism of action of 3-FMC strongly suggests that abuse of this synthetic cathinone may disturb neuronal homeostasis and impair functioning of the central nervous system.

Funding Information

This work was supported by grant no. MN 01-0039/08 from the Medical University of Gdańsk (Gdańsk, Poland).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. ACMD (2010a) Advisory Council on the Misuse of Drugs. Consideration of the naphthylpyrovalerone analogues and related compounds. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119085/naphyrone-report.pdf. Accessed 5 Feb 2018
  2. ACMD (2010b) Advisory Council on the Misuse of Drugs. ACMD report on the consideration of the cathinones https://wwwgovuk/government/uploads/system/uploads/attachment_data/file/119173/acmd-cathinodes-report-2010pdf. Accessed 5 Feb 2018
  3. Adamowicz P, Tokarczyk B, Stanaszek R, Slopianka M. Fatal mephedrone intoxication—a case report. J Anal Toxicol. 2013;37:37–42. doi: 10.1093/jat/bks085. [DOI] [PubMed] [Google Scholar]
  4. Angoa-Pérez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, Thomas DM, Kuhn DM. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. 2012;120:1097–1107. doi: 10.1111/j.1471-4159.2011.07632.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Angoa-Pérez M, Kane MJ, Herrera-Mundo N, Francescutti DM, Kuhn DM. Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci. 2014;97:31–36. doi: 10.1016/j.lfs.2013.07.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry. 2011;33:640.e5–640.e6. doi: 10.1016/j.genhosppsych.2011.04.010. [DOI] [PubMed] [Google Scholar]
  7. Assi S, Gulyamova N, Kneller P, Osselton D (2017) The effects and toxicity of cathinones from the users’ perspectives: a qualitative study. Hum Psychopharmacol 32(3). 10.1002/hup.2610 [DOI] [PubMed]
  8. Balint EE, Falkay G, Balint GA. Khat—a controversial plant. Wien Klin Wochenschr. 2009;121:604–614. doi: 10.1007/s00508-009-1259-7. [DOI] [PubMed] [Google Scholar]
  9. Baumann MH, Ayestas MA, Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37:1192–1203. doi: 10.1038/npp.2011.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38:552–562. doi: 10.1038/npp.2012.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Boulanger-Gobeil C, St-Onge M, Laliberté M, Auger PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol. 2012;8:59–61. doi: 10.1007/s13181-011-0159-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second-generation ‘legal highs’ in the UK: initial findings. Drug Test Anal. 2010;2:377–382. doi: 10.1002/dta.155. [DOI] [PubMed] [Google Scholar]
  13. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99:45–53. doi: 10.1016/S0163-7258(03)00052-4. [DOI] [PubMed] [Google Scholar]
  14. Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Mephedrone related fatalities: a review. Eur Rev Med Pharmacol Sci. 2015;19:3777–3790. [PubMed] [Google Scholar]
  15. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32:117–131. doi: 10.1016/S0197-0186(97)00031-4. [DOI] [PubMed] [Google Scholar]
  16. Cai Y, Arikkath J, Yang L, Guo ML, Periyasamy P, Buch S. Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy. 2016;12:225–244. doi: 10.1080/15548627.2015.1121360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cao L, Walker MP, Vaidya NK, Fu M, Kumar S, Kumar A. Cocaine-mediated autophagy in astrocytes involves sigma 1 receptor, PI3K, mTOR, Atg5/7, Beclin-1 and induces type II programed cell death. Mol Neurobiol. 2016;53:4417–4430. doi: 10.1007/s12035-015-9377-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. 2011;118:19–22. doi: 10.1016/j.drugalcdep.2011.02.011. [DOI] [PubMed] [Google Scholar]
  19. Chandramani Shivalingappa P, Jin H, Anantharam V, Kanthasamy A, Kanthasamy A. N-acetyl cysteine protects against methamphetamine-induced dopaminergic neurodegeneration via modulation of redox status and autophagy in dopaminergic cells. Parkinsons Dis. 2012;2012:424285. doi: 10.1155/2012/424285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Corkery JM, Schifano F, Hamid Ghodse A. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. Pharmacology. 2012;17:255–380. [Google Scholar]
  21. Cosbey SH, Peters KL, Quinn A, Bentley A. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J Anal Toxicol. 2013;37:74–82. doi: 10.1093/jat/bks094. [DOI] [PubMed] [Google Scholar]
  22. Cozzi NV, Sievert MK, Shulgin AT, Jacob P, 3rd, Ruoho AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol. 1999;381:63–69. doi: 10.1016/S0014-2999(99)00538-5. [DOI] [PubMed] [Google Scholar]
  23. den Hollander B, Schouw M, Groot P, Huisman H, Caan M, Barkhof F, Reneman L. Preliminary evidence of hippocampal damage in chronic users of ecstasy. J Neurol Neurosurg Psychiatry. 2012;83:83–85. doi: 10.1136/jnnp.2010.228387. [DOI] [PubMed] [Google Scholar]
  24. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER. Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone. Pharmacol Biochem Behav. 2013;103:501–529. doi: 10.1016/j.pbb.2012.10.006. [DOI] [PubMed] [Google Scholar]
  25. EMCDDA (2010) European Monitoring Centre for Drugs and Drug Addiction. Europol–EMCDDA Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone), http://www.emcdda.europa.eu/attachements.cfm/att_132203_EN_2010_Mephedrone_Joint%20report.pdf. Accessed 5 Feb 2018
  26. EMCDDA (2017) European Monitoring Centre for Drug and Drug Addiction. European drug report: trends and developments http://wwwemcddaeuropaeu/system/files/publications/4541/TDAT17001ENNpdf. Accessed 5 Feb 2018
  27. Eskelinen EL. Maturation of autophagic vacuoles in mammalian cells. Autophagy. 2005;1:1–10. doi: 10.4161/auto.1.1.1270. [DOI] [PubMed] [Google Scholar]
  28. Eskelinen EL. The dual role of autophagy in cancer. Curr Opin Pharmacol. 2011;11:294–300. doi: 10.1016/j.coph.2011.03.009. [DOI] [PubMed] [Google Scholar]
  29. Freeman TP, Morgan CJ, Vaughn-Jones J, Hussain N, Karimi K, Curran HV. Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’. Addiction. 2012;107:792–800. doi: 10.1111/j.1360-0443.2011.03719.x. [DOI] [PubMed] [Google Scholar]
  30. Fukui M, Song JH, Choi J, Choi HJ, Zhu BT. Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. Eur J Pharmacol. 2009;617:1–11. doi: 10.1016/j.ejphar.2009.06.059. [DOI] [PubMed] [Google Scholar]
  31. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, el-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nuñez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–120. doi: 10.1038/cdd.2011.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Gardner H, Lawn N, Fatovich DM, Archer JS. Acute hippocampal sclerosis following ecstasy ingestion. Neurology. 2009;73:567–569. doi: 10.1212/WNL.0b013e3181b2a684. [DOI] [PubMed] [Google Scholar]
  33. Gliyazova NS, Ibeanu GC. The chemical molecule B355252 is neuroprotective in an in vitro model of Parkinson’s disease. Cell Mol Neurobiol. 2016;36:1109–1122. doi: 10.1007/s10571-015-0304-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. 2011;339:530–536. doi: 10.1124/jpet.111.184119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Halliwell B. Free radicals, proteins and DNA: oxidative damage versus redox regulation. Biochem Soc Trans. 1996;24:1023–1027. doi: 10.1042/bst0241023. [DOI] [PubMed] [Google Scholar]
  36. Huang NK, Wan FJ, Tseng CJ, Tung CS. Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci. 1997;61:2219–2229. doi: 10.1016/S0024-3205(97)00924-7. [DOI] [PubMed] [Google Scholar]
  37. Huang YN, Yang LY, Wang JY, Lai CC, Chiu CT, Wang JY. L-ascorbate protects against methamphetamine-induced neurotoxicity of cortical cells via inhibiting oxidative stress, autophagy, and apoptosis. Mol Neurobiol. 2017;54:125–136. doi: 10.1007/s12035-015-9561-z. [DOI] [PubMed] [Google Scholar]
  38. Imam SF, Patel H, Mahmoud M, Prakash NA, King MS, Fremont RD. Bath salts intoxication: a case series. J Emerg Med. 2013;45:361–365. doi: 10.1016/j.jemermed.2013.04.017. [DOI] [PubMed] [Google Scholar]
  39. Jensen P, Myhre CL, Lassen PS, Metaxas A, Khan AM, Lambertsen KL, Babcock AA, Finsen B, Larsen MR, Kempf SJ. TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomics. Oncotarget. 2017;8:60223–60242. doi: 10.18632/oncotarget.19428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kang KS, Yamabe N, Wen Y, Fukui M, Zhu BT. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. Brain Res. 2013;1497:1–14. doi: 10.1016/j.brainres.2012.11.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Kanthasamy A, Anantharam V, Ali SF, Kanthasamy AG. Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death. Ann N Y Acad Sci. 2006;1074:234–244. doi: 10.1196/annals.1369.022. [DOI] [PubMed] [Google Scholar]
  42. Kempermann G, Song H, Gage FH. Neurogenesis in the adult hippocampus. Cold Spring Harb Perspect Biol. 2015;7:a018812. doi: 10.1101/cshperspect.a018812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, al-Younes HM, al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi RK, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NYO, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ETW, Juhász G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LAM, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RCC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SSL, Chen WL, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CHK, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AMK, Choi DS, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RSB, Clarke PGH, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D’Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, de Felici M, de Groot JF, de Haan CAM, de Martino L, de Milito A, de Tata V, Debnath J, Degterev A, Dehay B, Delbridge LMD, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, di Gioacchino M, di Paolo G, di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff KE, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, el-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farre JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, González-Estévez C, González-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson ÅB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi SI, Hazelhurst LA, He C, He YW, Hébert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Höhfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Høyer-Hansen M, Hu B, Hu CAA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SNA, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe KI, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jäättelä M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jiang X, Jiménez A, Jin M, Jin SV, Joe CO, Johansen T, Johnson DE, Johnson GVW, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhász G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kågedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JAKW, Kiger AA, Kihara A, Kim DR, Kim DH, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BCB, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Flores JBK, Kovács AL, Kraft C, Krainc D, Krämer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Krüger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, la Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, László L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, le W, le Cam L, Ledbetter DJ, Lee AJX, Lee BW, Lee GM, Lee J, lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, López-Otín C, Lossi L, Lotze MT, Low P, Lu B, Lu B, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MCV, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Mariño G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin BA, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Meléndez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RFS, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PAM, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CEH, Müller S, Muller S, Münger K, Münz C, Murphy LO, Murphy ME, Musarò A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nürnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JHJ, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Pöggeler S, Poirot M, Poletti A, Poüs C, Pozuelo-Rubio M, Prætorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Régnier-Vigouroux A, Reichert AS, Reiners JJ, Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodríguez de Córdoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KMA, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AMJ, Sánchez-Alcázar JA, Sánchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AHV, Scharl M, Schätzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schüller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin ECM, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Strålfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJY, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeyer H, Tafani M, Takács-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KSW, Tanaka K, Tanaka K, Tang D, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian FF, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tönges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, van den Berghe G, van der Klei IJ, van Doorn WG, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang XJ, Wang YJ, Wang Y, Wang ZB, Wang ZC, Wang Z, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WKK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ, III, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445–544. doi: 10.4161/auto.19496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9:1004–1010. doi: 10.1038/nrm2529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kumari S, Mehta SL, Li PA. Glutamate induces mitochondrial dynamic imbalance and autophagy activation: preventive effects of selenium. PLoS One. 2012;7:e39382. doi: 10.1371/journal.pone.0039382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci. 2002;22:8951–8960. doi: 10.1523/JNEUROSCI.22-20-08951.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Li IH, Ma KH, Weng SJ, Huang SS, Liang CM, Huang YS. Autophagy activation is involved in 3,4-methylenedioxymethamphetamine (‘ecstasy’)—induced neurotoxicity in cultured cortical neurons. PLoS One. 2014;9:e116565. doi: 10.1371/journal.pone.0116565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Li IH, Ma KH, Kao TJ, Lin YY, Weng SJ, Yen TY, Chen LC, Huang YS. Involvement of autophagy upregulation in 3,4-methylenedioxymethamphetamine (‘ecstasy’)-induced serotonergic neurotoxicity. Neurotoxicology. 2016;52:114–126. doi: 10.1016/j.neuro.2015.11.009. [DOI] [PubMed] [Google Scholar]
  49. Liu B, Ouyang L (2014) Involvement of autophagy and apoptosis in studies of anticancer drugs. In: Hayat MA (ed) Autophagy: cancer, other pathologies, inflammation, immunity, infection, and aging, vol 3. Academic, Elsevier, pp 263–287. 10.1016/B978-0-12-405529-2.00018-4
  50. López-Arnau R, Martínez-Clemente J, Abad S, Pubill D, Camarasa J, Escubedo E. Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse. Psychopharmacology. 2014;231:3119–3129. doi: 10.1007/s00213-014-3493-6. [DOI] [PubMed] [Google Scholar]
  51. López-Arnau R, Martínez-Clemente J, Rodrigo T, Pubill D, Camarasa J, Escubedo E. Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone. Toxicol Appl Pharmacol. 2015;286:27–35. doi: 10.1016/j.taap.2015.03.015. [DOI] [PubMed] [Google Scholar]
  52. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int. 2011;206:e93–e95. doi: 10.1016/j.forsciint.2010.12.014. [DOI] [PubMed] [Google Scholar]
  53. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol. 2013;37:135–146. doi: 10.1093/jat/bks136. [DOI] [PubMed] [Google Scholar]
  54. Martínez-Clemente J, López-Arnau R, Carbó M, Pubill D, Camarasa J, Escubedo E. Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology. 2013;229:295–306. doi: 10.1007/s00213-013-3108-7. [DOI] [PubMed] [Google Scholar]
  55. Martínez-Clemente J, López-Arnau R, Abad S, Pubill D, Escubedo E, Camarasa J. Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS One. 2014;9:e99002. doi: 10.1371/journal.pone.0099002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Marusich JA, Grant KR, Blough BE, Wiley JL. Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology. 2012;33:1305–1313. doi: 10.1016/j.neuro.2012.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol. 2011;35:188–191. doi: 10.1093/anatox/35.3.188. [DOI] [PubMed] [Google Scholar]
  58. Matsunaga T, Morikawa Y, Kamata K, Shibata A, Miyazono H, Sasajima Y, Suenami K, Sato K, Takekoshi Y, Endo S, El-Kabbani O, Ikari A. α-Pyrrolidinononanophenone provokes apoptosis of neuronal cells through alterations in antioxidant properties. Toxicology. 2017;386:93–102. doi: 10.1016/j.tox.2017.05.017. [DOI] [PubMed] [Google Scholar]
  59. Mercer LD, Higgins GC, Lau CL, Lawrence AJ, Beart PM. MDMA-induced neurotoxicity of serotonin neurons involves autophagy and rilmenidine is protective against its pathobiology. Neurochem Int. 2017;105:80–90. doi: 10.1016/j.neuint.2017.01.010. [DOI] [PubMed] [Google Scholar]
  60. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV) J Med Toxicol. 2012;8:69–75. doi: 10.1007/s13181-011-0196-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Parrott AC. Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology. 2000;42:17–24. doi: 10.1159/000026666. [DOI] [PubMed] [Google Scholar]
  62. Persona K, Polus A, Góralska J, Gruca A, Dembińska-Kieć A, Piekoszewski W. An in vitro study of the neurotoxic effects of N-benzylpiperazine: a designer drug of abuse. Neurotox Res. 2016;29:558–568. doi: 10.1007/s12640-016-9604-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Prokhorova EA, Zamaraev AV, Kopeina GS, Zhivotovsky B, Lavrik IN. Role of the nucleus in apoptosis: signaling and execution. Cell Mol Life Sci. 2015;72:4593–4612. doi: 10.1007/s00018-015-2031-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8:33–42. doi: 10.1007/s13181-011-0193-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 2001;358:1864–1869. doi: 10.1016/S0140-6736(01)06888-X. [DOI] [PubMed] [Google Scholar]
  66. Rogov V, Dötsch V, Johansen T, Kirkin V. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell. 2014;53:167–178. doi: 10.1016/j.molcel.2013.12.014. [DOI] [PubMed] [Google Scholar]
  67. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol. 2012;32:710–714. doi: 10.1097/JCP.0b013e318266c70c. [DOI] [PubMed] [Google Scholar]
  68. Siedlecka-Kroplewska K, Szczerba A, Lipinska A, Slebioda T, Kmiec Z. 3-Fluoromethcathinone, a structural analog of mephedrone, inhibits growth and induces cell cycle arrest in HT22 mouse hippocampal cells. J Physiol Pharmacol. 2014;65:241–246. [PubMed] [Google Scholar]
  69. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458–470. doi: 10.1111/j.1476-5381.2012.02145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Simmler LD, Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology. 2014;79:152–160. doi: 10.1016/j.neuropharm.2013.11.008. [DOI] [PubMed] [Google Scholar]
  71. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24:6028–6036. doi: 10.1523/JNEUROSCI.0713-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis. 2008;13:1–9. doi: 10.1007/s10495-007-0154-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Tian C, Murrin LC, Zheng JC. Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells. PLoS One. 2009;4:e5546. doi: 10.1371/journal.pone.0005546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Valente MJ, Amaral C, Correia-da-Silva G, Duarte JA, Bastos ML, Carvalho F, Guedes de Pinho P, Carvalho M. Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol. 2017;91:3663–3676. doi: 10.1007/s00204-017-1984-z. [DOI] [PubMed] [Google Scholar]
  75. Vallersnes OM, Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Euro-DEN Research Group. Dargan PI. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293. doi: 10.1186/s12888-016-1002-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol. 2012;8:65–68. doi: 10.1007/s13181-011-0199-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Wikström M, Thelander G, Nyström I, Kronstrand R. Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone) J Anal Toxicol. 2010;34:594–598. doi: 10.1093/jat/34.9.594. [DOI] [PubMed] [Google Scholar]
  78. Winder GS, Stern N, Hosanagar A. Are “bath salts” the next generation of stimulant abuse? J Subst Abus Treat. 2013;44:42–45. doi: 10.1016/j.jsat.2012.02.003. [DOI] [PubMed] [Google Scholar]
  79. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction. 2011;106:154–161. doi: 10.1111/j.1360-0443.2010.03130.x. [DOI] [PubMed] [Google Scholar]
  80. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106:1991–1996. doi: 10.1111/j.1360-0443.2011.03502.x. [DOI] [PubMed] [Google Scholar]
  81. Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z. Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol. 2011;103:55–98. doi: 10.1016/B978-0-12-385493-3.00004-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Wojcieszak J, Andrzejczak D, Woldan–Tambor A, Zawilska JB. Cytotoxic activity of pyrovalerone derivatives, an emerging group of psychostimulant designer cathinones. Neurotox Res. 2016;30:239–250. doi: 10.1007/s12640-016-9640-6. [DOI] [PubMed] [Google Scholar]
  83. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28:280–282. doi: 10.1136/emj.2010.092288. [DOI] [PubMed] [Google Scholar]
  84. Wu H, Che X, Zheng Q, Wu A, Pan K, Shao A, Wu Q, Zhang J, Hong Y. Caspases: a molecular switch node in the crosstalk between autophagy and apoptosis. Int J Biol Sci. 2014;10:1072–1083. doi: 10.7150/ijbs.9719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22:124–131. doi: 10.1016/j.ceb.2009.11.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther. 2011;11:169–176. doi: 10.4161/cbt.11.2.14663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Yang EJ, Ahn S, Ryu J, Choi MS, Choi S, Chong YH, Hyun JW, Chang MJ, Kim HS. Phloroglucinol attenuates the cognitive deficits of the 5XFAD mouse model of Alzheimer’s disease. PLoS One. 2015;10:e0135686. doi: 10.1371/journal.pone.0135686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Yonelinas AP. The hippocampus supports high-resolution binding in the service of perception, working memory and long-term memory. Behav Brain Res. 2013;254:34–44. doi: 10.1016/j.bbr.2013.05.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Zawilska JB, Wojcieszak J. Designer cathinones—an emerging class of novel recreational drugs. Forensic Sci Int. 2013;231:42–53. doi: 10.1016/j.forsciint.2013.04.015. [DOI] [PubMed] [Google Scholar]

Articles from Neurotoxicity Research are provided here courtesy of Springer

RESOURCES